Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham R Foster

Showing results (121-130 of 191) with videos related to

Pageof 20
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|July 31, 2017
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosisTarik Asselah, Stefan Bourgeois, Stephen Pianko, et al.
Journal of Hepatology|July 6, 2015
Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis BHenry Lik-Yuen Chan, Magdy Elkhashab, Huy Trinh, et al.
Drug and Alcohol Dependence|December 12, 2018
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studiesGraham R Foster, Gregory J Dore, Stanley Wang, et al.
Journal of Hepatology|July 9, 2016
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosisMichelle C M Cheung, Alex J Walker, Benjamin E Hudson, et al.
Journal of Hepatology|December 3, 2014
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infectionKosh Agarwal, Scott K Fung, Tuan T Nguyen, et al.
Journal of Hepatology|February 2, 2016
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosisGraham R Foster, William L Irving, Michelle C M Cheung, et al.
Gastroenterology|August 7, 2015
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infectionGraham R Foster, Stephen Pianko, Ashley Brown, et al.
Journal of Hepatology|November 28, 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster, Stefan Zeuzem, Pietro Andreone, et al.
Nature Communications|October 21, 2021
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failureDavid A Smith, Carlota Fernandez-Antunez, Andrea Magri, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 9, 2013
Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsisWilliam Alazawi, Helen Heath, Jennifer A Waters, et al.
Pageof 20

Showing results (121-130 of 191) with videos related to

Sort By:
Pageof 20
Liver International : Official Journal of the International Association for the Study of the Liver|July 31, 2017
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosisTarik Asselah, Stefan Bourgeois, Stephen Pianko, et al.
Journal of Hepatology|July 6, 2015
Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis BHenry Lik-Yuen Chan, Magdy Elkhashab, Huy Trinh, et al.
Drug and Alcohol Dependence|December 12, 2018
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studiesGraham R Foster, Gregory J Dore, Stanley Wang, et al.
Journal of Hepatology|July 9, 2016
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosisMichelle C M Cheung, Alex J Walker, Benjamin E Hudson, et al.
Journal of Hepatology|December 3, 2014
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infectionKosh Agarwal, Scott K Fung, Tuan T Nguyen, et al.
Journal of Hepatology|February 2, 2016
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosisGraham R Foster, William L Irving, Michelle C M Cheung, et al.
Gastroenterology|August 7, 2015
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infectionGraham R Foster, Stephen Pianko, Ashley Brown, et al.
Journal of Hepatology|November 28, 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster, Stefan Zeuzem, Pietro Andreone, et al.
Nature Communications|October 21, 2021
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failureDavid A Smith, Carlota Fernandez-Antunez, Andrea Magri, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 9, 2013
Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsisWilliam Alazawi, Helen Heath, Jennifer A Waters, et al.
Pageof 20